Page last updated: 2024-12-07
19-noraldosterone
## 19-Noraldosterone: A Potent Mineralocorticoid Receptor Agonist
**19-Noraldosterone** is a synthetic steroid hormone that acts as a potent agonist for the **mineralocorticoid receptor (MR)**. It is a derivative of aldosterone, a natural hormone produced by the adrenal glands that plays a crucial role in regulating blood pressure and electrolyte balance.
**Here's why it's important for research:**
* **Understanding Mineralocorticoid Receptor Function:** 19-noraldosterone is a valuable tool for studying the MR, as it provides a potent and selective activation of the receptor. Researchers can use it to investigate the complex signaling pathways involved in MR activation and its downstream effects.
* **Developing Novel MR Modulators:** Due to its potent MR activity, 19-noraldosterone has been studied as a potential therapeutic agent for treating conditions such as heart failure and hypertension. However, its clinical use is limited due to its potent effects on sodium retention and potassium excretion.
* **Investigating Aldosterone's Pathological Role:** 19-noraldosterone is helpful in studying the role of aldosterone in various diseases, including heart failure, kidney disease, and metabolic disorders. Its use in experimental models allows researchers to mimic the effects of aldosterone excess, leading to a better understanding of its detrimental effects.
* **Developing Novel Diagnostic Tools:** 19-noraldosterone can be used to develop more sensitive and specific diagnostic tools for identifying aldosterone excess, which is a condition that can lead to hypertension and other health problems.
**Important Considerations:**
* 19-noraldosterone is a powerful compound and should be used with caution, as it can cause significant side effects.
* Its potent mineralocorticoid activity can lead to adverse effects like hyperkalemia (elevated potassium levels) and fluid retention.
* It's important to use 19-noraldosterone in controlled research settings under the supervision of trained professionals.
**Overall, 19-noraldosterone is a valuable research tool that provides insights into the function of the MR, helps in the development of novel therapeutics and diagnostics, and aids in understanding the pathological role of aldosterone in various diseases.**
Cross-References
ID Source | ID |
PubMed CID | 127113 |
CHEBI ID | 175411 |
SCHEMBL ID | 21919837 |
MeSH ID | M0089360 |
Synonyms (9)
Synonym |
76025-75-7 |
(8s,9s,10r,11s,13r,14s,17s)-11-hydroxy-17-(2-hydroxyacetyl)-3-oxo-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-13-carbaldehyde |
CHEBI:175411 |
19-noraldosterone |
19-norpregn-4-en-18-al, 11,21-dihydroxy-3,20-dioxo-, (11beta)- |
(1s,2r,10s,11s,14s,15r,17s)-17-hydroxy-14-(2-hydroxyacetyl)-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-ene-15-carbaldehyde |
SCHEMBL21919837 |
DTXSID90997374 |
11,21-dihydroxy-3,20-dioxo-19-norpregn-4-en-18-al |
Drug Classes (1)
Class | Description |
21-hydroxy steroid | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (17)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 5 (29.41) | 18.7374 |
1990's | 11 (64.71) | 18.2507 |
2000's | 1 (5.88) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.52
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
Metric | This Compound (vs All) |
---|
Research Demand Index | 11.52 (24.57) | Research Supply Index | 2.89 (2.92) | Research Growth Index | 4.41 (4.65) | Search Engine Demand Index | 0.00 (26.88) | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 3 (17.65%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 14 (82.35%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |